Evidence map›Paper›PMID 40898614›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy.

Thanich Sangsuwannukul, Benjamin Kendall, Jason Tonne, Olivia Liseth, Jill Thompson, Kamonlapat Supimon, Muriel M Metko, Alex Chen, Maria P Chiriboga Yerovi, Rosa Maria Diaz and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Thanich SangsuwannukulDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Benjamin KendallDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Jason TonneDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Olivia LisethDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Jill ThompsonDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Kamonlapat SupimonDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Muriel M MetkoDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Alex ChenDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Maria P Chiriboga YeroviDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Rosa Maria DiazDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Laura EvginDepartment of Medical Genetics, University of British Columbia, Vancouver, BC V5Z1L3, Canada; Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Mason J WebbDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA; Department of Hematology/Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Jacob van VlotenDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Satdarshan P MongaOrgan Pathobiology and Therapeutics Institute and Pittsburgh Liver Research Center, University of Pittsburgh and UPMC, Pittsburgh, PA 15261, USA.
Sheeba IrshadComprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Breast Cancer Now Research Unit, King's College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
Mark McNivenMayo Center for Biomedical Discovery, Mayo Clinic, Rochester, MN 55905, USA.
Lewis RobertsDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Richard G VileDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA; Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA; Joan Reece Chair of Immuno-oncology, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, and School of Immunology and Microbial Sciences, Kings College London, London, UK. Electronic address: vile.richard@mayo.edu.

Funding

Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Zongming Eric Chen · 2018 to 2026
$20.5M
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.R01AI170535 · NIAID · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.6M
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.R01CA269384 · NCI · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.4M
PhD Training Program in Virology and Gene TherapyT32AI132165 · NIAID · MAYO CLINIC ROCHESTER · PI ROBERTO B. CATTANEO · 2018 to 2026
$1.3M
NCI NIH HHS P50 CA210964NCI NIH HHS R01 CA269384NIAID NIH HHS R01 AI170535NIAID NIH HHS T32 AI132165
6 · The paper itself

Abstract

Currently, the benefits of immune checkpoint blockade (ICB) for hepatocellular carcinoma (HCC) are restricted to a subset of patients. We hypothesized that co-treatment with the inflammatory oncolytic virus (OV) vesicular stomatitis virus (VSV-IFNβ) would reprogram the highly immunosuppressive tumor microenvironment (TME) to enhance ICB. However, VSV-IFNβ inhibited the efficacy of ICB. To develop better, mechanism-based immunotherapies for HCC, here, we characterized (1) the baseline T cell response to HCC, (2) its enhancement by ICB, (3) the inhibitory effects of VSV, and (4) the antigenic response of HCC to treatment. We show that a slowly developing anti-tumor CD8

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsOncolytic VirotherapyAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapyMiceOncolytic VirusesT-Cell ExhaustionTumor MicroenvironmentImmune Checkpoint Inhibitorsantitumor immunityantiviral immunityCD39CD8 T cellshepatocellular carcinomah-Met/β-catenin Sleeping Beauty transposonimmune checkpoint blockadePD-1/PD-L1vesicular stomatitis virus

Identifiers

PMID40898614
PMCPMC12703176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.